Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aaron T Gerds

Showing results (61-70 of 137) with videos related to

Pageof 14
Sort By:
Blood Advances|December 21, 2021
Atezolizumab alone or in combination did not demonstrate a favorable risk-benefit profile in myelodysplastic syndromeAaron T Gerds, Bart L Scott, Peter Greenberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 4, 2018
Reply to A. Piccardo et al, E. Hindié et al, M.C. Kreissl et al, M. Doss, J. Buscombe, R. Fisher, M. Sollini et al, M. Lichtenstein, and M. Tulchinsky et alRemco J Molenaar, Surbhi Sidana, Tomas Radivoyevitch, et al.
Leukemia Research|March 9, 2019
Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinibAaron T Gerds, Tetsuzo Tauchi, Ellen Ritchie, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 15, 2023
Real-World Use of Fedratinib for Myelofibrosis Following Prior Ruxolitinib Failure: Patient Characteristics, Treatment Patterns, and Clinical OutcomesJohn Mascarenhas, Claire Harrison, Tammy A Schuler, et al.
American Journal of Hematology|April 5, 2017
The association of histologic grade with acute graft-versus-host disease response and outcomesMayur Narkhede, Lisa Rybicki, Donna Abounader, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 21, 2016
Association of Socioeconomic Status with Outcomes of Autologous Hematopoietic Cell Transplantation for Multiple MyelomaSanghee Hong, Lisa Rybicki, Donna Abounader, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 26, 2018
Prognostic Factors for Mortality among Day +100 Survivors after Allogeneic Hematopoietic Cell TransplantationSagar S Patel, Lisa A Rybicki, Donna Corrigan, et al.
Blood Neoplasia|October 28, 2025
Disparities in real-world treatment patterns of hypomethylating agents among patients with MDS in the United StatesSudipto Mukherjee, Weichuan Dong, Aaron T Gerds, et al.
Leukemia & Lymphoma|August 31, 2017
Prognostic value of pre-transplant PET/CT in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantationAllison Winter, Lisa Rybicki, Shetal N Shah, et al.
Blood Cancer Journal|January 12, 2018
Mutations in DNMT3A, U2AF1, and EZH2 identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1Caner Saygin, Cassandra Hirsch, Bartlomiej Przychodzen, et al.
Pageof 14

Showing results (61-70 of 137) with videos related to

Sort By:
Pageof 14
Blood Advances|December 21, 2021
Atezolizumab alone or in combination did not demonstrate a favorable risk-benefit profile in myelodysplastic syndromeAaron T Gerds, Bart L Scott, Peter Greenberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 4, 2018
Reply to A. Piccardo et al, E. Hindié et al, M.C. Kreissl et al, M. Doss, J. Buscombe, R. Fisher, M. Sollini et al, M. Lichtenstein, and M. Tulchinsky et alRemco J Molenaar, Surbhi Sidana, Tomas Radivoyevitch, et al.
Leukemia Research|March 9, 2019
Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinibAaron T Gerds, Tetsuzo Tauchi, Ellen Ritchie, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 15, 2023
Real-World Use of Fedratinib for Myelofibrosis Following Prior Ruxolitinib Failure: Patient Characteristics, Treatment Patterns, and Clinical OutcomesJohn Mascarenhas, Claire Harrison, Tammy A Schuler, et al.
American Journal of Hematology|April 5, 2017
The association of histologic grade with acute graft-versus-host disease response and outcomesMayur Narkhede, Lisa Rybicki, Donna Abounader, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 21, 2016
Association of Socioeconomic Status with Outcomes of Autologous Hematopoietic Cell Transplantation for Multiple MyelomaSanghee Hong, Lisa Rybicki, Donna Abounader, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 26, 2018
Prognostic Factors for Mortality among Day +100 Survivors after Allogeneic Hematopoietic Cell TransplantationSagar S Patel, Lisa A Rybicki, Donna Corrigan, et al.
Blood Neoplasia|October 28, 2025
Disparities in real-world treatment patterns of hypomethylating agents among patients with MDS in the United StatesSudipto Mukherjee, Weichuan Dong, Aaron T Gerds, et al.
Leukemia & Lymphoma|August 31, 2017
Prognostic value of pre-transplant PET/CT in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantationAllison Winter, Lisa Rybicki, Shetal N Shah, et al.
Blood Cancer Journal|January 12, 2018
Mutations in DNMT3A, U2AF1, and EZH2 identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1Caner Saygin, Cassandra Hirsch, Bartlomiej Przychodzen, et al.
Pageof 14